INM-755 (Cannabinol) Cream for Treatment of Epidermolysis Bullosa

Epidermolysis Bullosa Dystrophica Clinical Trial

Official title:

A Randomised, Double-Blind, Vehicle-Controlled Phase 2 Study of Topically Applied INM-755 (Cannabinol) Cream in Patients With Epidermolysis Bullosa

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04908215
• Other study ID #: 755-201-EB
• Status: Completed
• Phase: Phase 2
• Start date: December 28, 2021
• Est. completion date: April 19, 2023

Study information

• Verified date: June 2023
• Source: InMed Pharmaceuticals Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety of INM-755 (cannabinol) cream and obtain preliminary evidence of efficacy in treating symptoms and healing wounds over a 28-day period in patients with epidermolysis bullosa (EB).

Description:

This is an international, multicenter study to evaluate the safety and obtain preliminary evidence of efficacy of topically applied INM-755 (cannabinol) cream in up to 20 patients with inherited EB (Simplex, Dystrophic, Junctional, or Kindler). The study uses a within-patient, double-blind design in which matched index areas are randomized to INM-755 (cannabinol) cream or vehicle cream as a control. Selected index areas may be wounds or non-wound areas. Randomized treatments are applied daily to non-wound areas and every 1, 2, or 3 days on wounds, according to the patient's schedule for dressing changes. Treatment is over a 28-day period. EB symptoms are evaluated based on patient-reported outcomes. Wound healing is measured by digital photography. In this study designed to obtain preliminary evidence of efficacy, there is no single primary efficacy endpoint. Efficacy endpoints vary according to the presenting symptoms in each patient, which may include the presence of open wounds, wound pain associated with dressing changes, background wound pain (not procedurally linked), wound itch, and itch in non-wound areas. Net benefit from INM-755 cream is evaluated within each patient and based on their clinical needs at baseline. Enrollment is beginning with adults and may be expanded to include adolescents.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 19
• Est. completion date: April 19, 2023
• Est. primary completion date: April 3, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 12 Years and older

Eligibility

Key Inclusion Criteria:

• Male or female patients aged =18 years with documented diagnosis of any of the following types of inherited EB: Simplex, Junctional, Dystrophic, Kindler. Enrolment will be extended to patients =12 years old and <18 years old after positive opinion of a data monitoring committee after at least 4 adult patients have completed study.
• Presence of at least 1 pair of well-matched index areas. Up to 2 pairs of index areas (1 pair of non-wound and 1 pair of wound index areas) can be selected in each patient
• For non-wound itch index areas, both areas should:

1. Have chronic itch with a score =40 mm on a 100 mm VAS

2. Not exceed 20 percent of body surface area (BSA) or be less than 1 percent of BSA

3. Be similar size, up to twice the area of the smaller index area

• For wound index areas, both wounds should:

1. Have a surface area =5 cm^2 and =50 cm^2 inclusive and be aged =3 weeks

2. Be well matched for size (up to twice the area of the smaller index area) and age (both either =3 weeks to 3 months or >3 months)

• Female patients of childbearing potential or men whose sexual partners are women of childbearing potential (WOCBP) must use highly effective birth control
• WOCBP must have a negative urine pregnancy test result at baseline
• Must provide written consent (or assent for patients aged <18 years with parental/guardian consent)

Key Exclusion Criteria:

• EB index areas have evidence of infection
• Patient has a systemic infection or used systemic antibiotics for EB-related infections within 7 days
• Use of systemic corticosteroids within 30 days or of topical corticosteroids on chosen index areas within 14 days
• Immunosuppressive therapy or cytotoxic chemotherapy within 60 days
• Use of any high potency opioid within 30 days
• Use of cannabis, cannabis extracts, or any cannabinoid products for medical or recreational use by any route of administration within 2 weeks
• Prior stem cell transplant or gene therapy for EB
• History of malignancy including basal cell and squamous cell carcinomas
• Arterial or venous disorder resulting in ulcerated wounds
• Uncontrolled diabetes mellitus
• Chronic pruritus primarily attributable to pathologies or conditions other than EB
• Blood transfusion to treat anemia within the past 3 months
• Use of any investigational drug within 30 days or 5 half-lives (whichever is longer)
• An underlying condition which places the patient at unacceptable risk
• Women who are pregnant, breastfeeding (lactating), or planning to become pregnant during the study

Related Conditions & MeSH terms

• Epidermolysis Bullosa
• Epidermolysis Bullosa Dystrophica
• Epidermolysis Bullosa Simplex
• Epidermolysis Bullosa, Junctional

Intervention

Drug:
• INM-755 (cannabinol) cream
topical cream containing cannabinol for dermal application
• Vehicle Cream
topical cream base for dermal application containing no active agent

Locations

Country	Name	City	State
France	Hopital Saint Louis APHP Paris	Paris
France	CHU Toulouse - Hopital Larrey	Toulouse
Germany	Universitaetsklinikum Freiburg	Freiburg
Greece	Andreas Syggros Hospital of Cutaneous Venereal Diseases	Athens
Israel	Tel Aviv Sourasky Medical Center	Tel Aviv
Italy	Fondazione IRCCS Ca Granda. Ospedale Maggiore Policlinico	Milan	Milano
Italy	Instituto Dermopatico dell'Immacolata, IDI-IRCCS	Rome	Roma

Sponsors (1)

Lead Sponsor	Collaborator
InMed Pharmaceuticals Inc.

Countries where clinical trial is conducted

France,  Germany,  Greece,  Israel,  Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from Baseline in Non-Wound Itch by Visual Analogue Scale (VAS)	Patients will report peak (maximal) pruritus intensity over the previous 24 hours using a 100 mm VAS (0 being "no itch" to 100 mm being "worst imaginable itch") recorded daily in the study diary. This outcome measure is applicable only for patients with non-wound index areas with eligible (moderate to severe) itch.	Baseline to Day 29
Primary	Change from Baseline in Wound Surface Area	Wound surface area will be measured by digital photography at weekly intervals. This outcome measure is applicable only for patients with wound index areas.	Baseline to Day 29
Primary	Change from Baseline in Procedural Wound Pain by VAS	Patients will report wound pain intensity using a 100 mm VAS (0 being "no pain" to 100 mm being "worst imaginable pain") and this will be recorded in the study diary. Procedural pain will be assessed immediately after each wound dressing, which may be every 1, 2, or 3 days according to an individual patient's schedule for dressing change. This outcome measure is applicable only for patients with wound index areas associated with eligible (moderate to severe) procedural pain.	Baseline to Day 29
Primary	Change from Baseline in Background Wound Pain by VAS	Patients will report wound pain intensity using a 100 mm VAS (0 being "no pain" to 100 mm being "worst imaginable pain") and this will be recorded in the study diary. Peak (maximal) background pain will be assessed daily in the morning (done before the dressing change). This outcome measure is applicable only for patients with wound index areas associated with eligible (moderate to severe) background pain.	Baseline to Day 29
Primary	Change from Baseline in Wound Itch by VAS	Patients will report peak (maximal) pruritus intensity over the previous 24 hours using a 100 mm VAS (0 being "no itch" to 100 mm being "worst imaginable itch") recorded daily in the study diary. This outcome measure is applicable only for patients with wound index areas associated with eligible (moderate to severe) itch.	Baseline to Day 29